Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06003361
Other study ID # BH-D-02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 31, 2023
Est. completion date December 21, 2023

Study information

Verified date January 2024
Source Big Health Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the efficacy of digital CBT versus waitlist in improving symptoms for adults with Major Depressive Disorder.


Description:

This study aims to examine the effectiveness of app-based digital CBT in individuals with a diagnosis of Major Depressive Disorder. The primary outcomes are depression symptom reduction and engagement with fulfilling activities after 5 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date December 21, 2023
Est. primary completion date November 22, 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: - Adults aged =22 years old - Score =10 and <20 on the 8-item Patient Health Questionnaire (PHQ-8) - Diagnosis of Major Depression - Current resident of the USA - Oral and written fluency in English - Regular access to the internet via a mobile or tablet device using Android (5 or higher) or iOS (13 or higher) - Participant is able and willing to comply with protocol requirements, has been informed of the nature of the study, and has signed the IRB-approved informed consent form Exclusion Criteria: - Must not be currently receiving or be expecting to start therapy for depression, anxiety, or sleep during study participation, or have received cognitive behavioral therapy for depression, anxiety, or sleep in the past 12-months - If on psychotropic medication, this must be stable for at least 60 days - Past or present psychosis, schizophrenia, or bipolar disorder - Moderate or greater suicide risk - Treatment-resistant depression - Hearing or vision impairment that prevents effective use of the audio-visual content of digital CBT or psychoeducation - Intellectual disability or any Neurocognitive or Neurodevelopmental disorder that would prevent participants from following study procedures - Any condition that the investigator believes would make participation in the study not in the best interest of the subject or would preclude successful completion of study activities - Other exclusion criteria may apply

Study Design


Intervention

Device:
Digital CBT
An app-based intervention based on principles from cognitive behavioral therapy for depression.
Other:
Waitlist
Participants will wait for 5 weeks prior to receiving the intervention

Locations

Country Name City State
United States Big Health Inc. San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Big Health Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Health Questionnaire (PHQ-8) Validated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity 5 weeks post-randomization
Primary Environmental Reward Observation Scale (EROS) A validated 10 item scale with total scores between 10 and 40 where higher scores indicate greater engagement with rewarding or fulfilling life activities 5 weeks post-randomization
Secondary Patient Health Questionnaire (PHQ-8) Validated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity 10 weeks post-randomization
Secondary Montgomery-Åsberg Depression Rating Scale (MADRS) A validated 10 item observer-rated scale with total scores between 0 and 60 where higher scores indicate greater severity 5 and 10 weeks post-randomization
Secondary World Health Organization 5-item Wellbeing Index (WHO-5) Validated questionnaire; a 5-item scale with raw total scores between 0 and 25 where higher scores indicate greater wellbeing Weeks 5 and 10 post-randomization
Secondary Environmental Reward Observation Scale (EROS) A validated 10 item scale with total scores between 10 and 40 where higher scores indicate greater engagement with rewarding or fulfilling life activities 10 weeks post-randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4